Pkm2 can enhance pluripotency in ESCs and promote somatic cell reprogramming to iPSCs

Shengtang Qin; Danli Yang; Kang Chen; Haolan Li; Liqiang Zhang; Yuan Li; Rongrong Le; Xiaojie Li; Shaorong Gao; Lan Kang

doi:10.18632/oncotarget.20685

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Pkm2 can enhance pluripotency in ESCs and promote somatic cell reprogramming to iPSCs

Shengtang Qin, Danli Yang, Kang Chen, Haolan Li, Liqiang Zhang, Yuan Li, Rongrong Le, Xiaojie Li, Shaorong Gao and Lan Kang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:84276-84284. https://doi.org/10.18632/oncotarget.20685

Metrics: PDF 1638 views | HTML 2299 views | ?

Abstract

Shengtang Qin1,*, Danli Yang1,*, Kang Chen1,*, Haolan Li1, Liqiang Zhang1, Yuan Li1, Rongrong Le2, Xiaojie Li3, Shaorong Gao2 and Lan Kang1

1Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China

2School of Life Sciences and Technology, Tongji University, Shanghai 200092, China

3College of Stomatology, Dalian Medical University, Dalian 116044, China

*These authors have contributed equally to this work

Correspondence to:

Lan Kang, email: [email protected]

Shaorong Gao, email: [email protected]

Xiaojie Li, email: [email protected]

Keywords: Pkm2, ESC, iPSC, reprogramming, pluripotency

Received: April 27, 2017 Accepted: July 25, 2017 Published: September 06, 2017

ABSTRACT

Aerobic glycolysis is one of the most important common characteristics in both cancer cells and stem cells. Metabolism switch has been discovered as an important early event in the process of reprogramming somatic cells to induced pluripotent stem cells (iPSCs). As a rate limiting kinase in glycolysis, Pkm2 has been reported playing critical roles in many tumors, yet its role in stem cells and iPSCs induction is poorly defined. In the present study, we showed that Pkm2 is a predominant pyruvate kinase in embryonic stem cells (ESCs), and its expression increases many pluripotent genes. During somatic cell reprogramming, up-regulation of Pkm2 can be observed and over-expression of Pkm2 can facilitate iPSCs induction, while Pkm1 or a mutant form of Pkm2 (Pkm2^K422R) showed no enhancement role in iPSCs induction. Therefore, our data demonstrated that Pkm2 enhances the pluripotency maintenance in ESCs and promotes the pluripotency acquisition during somatic cell reprogramming.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20685

Publication Alerts

Research Papers:

Pkm2 can enhance pluripotency in ESCs and promote somatic cell reprogramming to iPSCs

Abstract